Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer

Inclusion Criteria: * Written informed consent obtained from the patient prior to performing any protocol-related procedures, including screening evaluations. * Female or male, Age ≥ 18 years at time of study entry. * Primitive triple negative breast cancer proven histologically, defined according to the following criteria: * Estrogen receptors \<10%. * And progesterone receptors \<10%. * And Human Epidermal Growth factor Receptor 2 (HER2) not amplified or not overexpressed. * Breast Cancer (BC) recurrence documented by conventional imaging and/or FDG PET/CT with at least one measurable metastatic lesion according to Response Evaluation Criteria In Solid Tumors (RECIST) and/or PET Response Criteria In Solid Tumors (PERCIST). * Consent to use a contraception method for at least 30 days after administration of 89Zr-TLX250. * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1. * Life expectancy at least 6 months. * Patient has valid health insurance. * Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up. Exclusion Criteria: * History of another primary malignancy except for basal cell carcinoma within the last 5 years. * Chemotherapy, radiotherapy, or immunotherapy within 4 weeks prior to the planned administration of 89Zr-TLX250 or continuing adverse effects (\> grade 1) from such therapy (Common Terminology Criteria for Adverse E…